Europe's Leading HGH Manufacturer
US$ 27.10
glp-1 pen injector components ServoPen | Reusable for GLP-1, Insulin & Other Peptide Therapies Five Unexpected New Uses for
Description
Your health is not a one-size-fits-all equation
Bone (2016) 82:429
doi: 10.1007/s40262-017-0532-6
Another competitor, tirzepatide (Mounjaro), is a dual GIP/GLP-1 receptor agonist targeting two hormones
And your baseline tolerance is more predictable
The first head-to-head clinical trial (SURMOUNT-5, published in the New England Journal of Medicine in 2025) showed tirzepatide produced 20.2% average weight loss at 72 weeks compared to 13.7% for semaglutide approximately 47% greater relative weight loss
